More companies enter the cold-chain distribution arena
Continuing growth attracts more players; meanwhile, Sensitech acquires FreightWatch International to beef up real-time monitoring
Evaluate Pharma predicts top companies, products in 2018
Novartis could overtake Pfizer as No. 1, while Merck's Januvia/Janumet franchise will approach $10 billion in annual sales
More cloak-and-dagger details about the 2010 Eli Lilly Enfield drug heist come out
Attempts were made to relabel stolen product with counterfeit labels, says NJ Star-Ledger
Walgreens-Alliance Boots merger could redefine retail pharmacy
Combination will create the world's largest single buyer of pharmaceuticals
Federal pedigree/track-and-trace rules appear to be dead, for now
FDA Safety and Innovation Act is ready for final passage
Carbon dioxide (CO2) emissions from cold-chain shipments can affect aircraft environments
FedEx takes precautionary steps to manage CO2 outgassing in their newest B-777 aircraft
PDUFA bumps its way toward passage
Meanwhile, all eyes were on the Supreme Court’s expected ruling on Obamacare
Pharma distribution technologies start heading for the 'cloud'
Systech builds on its packaging execution/serialization capabilities with an acquisition
A new source of pharma marketing analytics: Symphony Health Solutions
Private-equity firm builds a competitor in pharma sales analytics
High access to physicians by pharma reps correlates with faster uptake of new medical information
In-depth statistical analysis using ZS Associates and IMS Health prescriber data demonstrates the value of rep-sourced communication
Merck Serono and Dr. Reddy's will collaborate on biosimilars
Monoclonal antibodies (MAbs) for oncology will be initial target
A conversation with Jeffrey Berkowitz, Walgreens
The leading chain pharmacy steps up its role as healthcare provider and partner to pharma
Navigating the tense, complex oncology market
Oncology combines some of the most life-changing therapeutic events with the most complex commercialization pathways. Rising costs of treatments simply add to the tension
Compliance, technology energize the master-data management business
Compiling and maintaining lists of healthcare provider contacts is a bigger and more important task than ever
US House passes PDUFA reauthorization by 387-5; bill now heads for reconciliation with Senate version
House bill mostly parallels Senate’s S.3187; but lacks federal pedigree rules
2012 site selection report
Biopharma remains a bright spot in US and international economic activity, even while the overall outlook remains cloudy
Healthcare's 'third place--patient-centered healthcare--is life sciences' future business focus, says E&Y
Latest annual Progressions report highlights the shift to healthy behaviors
Supply chains for a patient-centric world
Tomorrow's healthcare market, driven by consumer choice and outcomes-driven economics, will create new supply chain models
FTC Approves Express Scripts/Medco Merger: Excerpts
Merger is not expected to affect specialty-distribution agreements negatively
Jobs and biopharma
Ten-year BLS projection sees a healthy industry ahead
US market for pharmaceuticals was $320 billion in 2011, says IMS Institute
Patient office visits, prescription usage continued to decline
NEHI: Medication adherence needs better coordination among stakeholders
Pharma industry serves best as underwriter of healthcare providers' efforts
Some good news on drug shortage--finally
Covis Pharmaceuticals' business model is to acquire distribution rights to low-volume drugs
A scientific approach to site selection
Applying a consistent framework to choose locations can help optimize R&D and drive cost reduction for pharmaceutical companies of all sizes
The shape and consequences of risk evaluation are measured in new Quintiles survey
US patients believe they are healthier than they actually are, and at the same time have a greater willingness to try new therapies
Drug shortages 2012: A worsening situation, but movement on industry response
Despite the lack of headlines today as compared to late last year, the drug-shortage situation has not improved. FDA, congressional and industry actions are beginning the change the dynamic
Cegedim profiles pharma promotional spending in the BRIC countries
Sampling and doctors’ meetings compete for the largest secondary promotional spending component, behind detailing, in the BRIC countries
